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Meta-Analysis of the Effect of Intravitreal Bevacizumab
Versus Intravitreal Triamcinolone Acetonide
in Central Retinal Vein Occlusion
Zi Ye Jin,1,* Dan Zhu,1,* Yong Tao,2 Ian Y. Wong,3 and Jost B. Jonas4
Abstract
Purpose: To further evaluate the effect of intravitreal bevacizumab (IVB) for the treatment of central retinal vein
occlusion (CRVO) by meta-analysis.
Methods: Pertinent publications were identified through PubMed, EMBASE, and the Cochrane Controlled Trials
Register up to 30 January 2013. Changes in central macular thickness (CMT) and best-corrected visual acuity
(BCVA) were extracted at 4, 12, and 24 weeks after treatment, and a meta-analysis was carried out to compare
results between groups receiving IVB and intravitreal triamcinolone acetonide (IVTA).
Results: One randomized controlled trial and 4 comparative studies were identified and included. All of
the funnel plots, the Egger’s method and Begg method did not show publication bias. Our meta-analysis
revealed that BCVA and CMT at 4, 12, and 24 weeks after treatment did not vary significantly between
the IVB groups and IVTA groups (BCVA: at 4 weeks, P = 0.27; at 12 weeks, P = 0.51; at 24 weeks, P = 0.64;
CMT at 4 weeks, P = 0.88; at 12 weeks, P = 0.57; at 24 weeks, P = 0.64). However, the rate of intraocular
pressure rise after intravitreal injection varied significantly between the IVB groups and IVTA groups
(P < 0.001).
Conclusions: Our results showed a similar improvement in BCVA and CMT among CRVO patients was ob-
tained after intravitreal injections of both IVB, or IVTA, while the rate of IOP rise was significantly higher in the
latter.
Introduction
Central retinal vein occlusion (CRVO) is a commonretinal vascular disorder in patients more than 50 years
old, and one of the commonest causes of visual loss in
CRVO patients is macular edema.1 Till now, numerous in-
terventions have been developed to tackle this, namely,
systemic anticoagulation, panretinal photocoagulation,
macular grid photocoagulation, hemodilution, laser chor-
ioretinal venous anastomosis, and radial optic neurotomy.
Nevertheless, there is still inadequate level I evidence to
show superiority in any specific regimen to improve vision
in CRVO patients.1–3
The panoply of therapeutic possibilities increased dra-
matically with the development of intravitreal medical
therapies, initially with the intravitreal use of triamcinolone
(IVTA),4–8 followed by the intravitreal application of bev-
acizumab (IVB), and subsequently, the other antivascular
endothelial growth factors in the recent 8 years.9–14 Although
reduction of macular thickness and improvement of vision
were observed after both treatments, as far as the authors
were aware, no systematic reviews comparing the thera-
peutic effects of IVB and IVTA for CRVO have been pub-
lished. It is necessary to review in greater depth, the benefits
and risks of IVB and IVTA for CRVO. We have performed a
meta-analysis to review the literature to compare the effect
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and safety profiles of both IVB and IVTA, in treating patients
with CRVO.
Methods
Two reviewers independently searched the following
electronic databases: PubMed, EMBASE, and the Cochrane
Controlled Trials Register up to January 30, 2013. Free text
and thesaurus terms, including ‘‘bevacizumab,’’ ‘‘triamcino-
lone acetonide,’’ ‘‘central retinal vein occlusion,’’ and ‘‘mac-
ular edema’’ were used. When titles and/or abstracts met the
objectives, the full article would be retrieved. A manual
cross-reference search for bibliographies of relevant articles
was also conducted. The inclusion criteria for references
were (1) all published studies comparing IVB versus IVTA
for CRVO, including randomized controlled trials (RCTs)
and high-quality comparative studies; and (2) all articles,
where pre- and post-treatment visual acuity and the mac-
ular thickness were measured and recorded. There was no
language restriction. For the publications from the same
group of authors, only the article with the largest number of
patients was used. The selected articles were then critically
appraised by 2 reviewers, who independently assessed
their quality using the modified Jadad score table.15 Para-
meters judging the methodological quality included allo-
cation concealment, the method of intervention allocation,
the degree of masking, and the completeness in subject
follow-up. The postoperative outcome parameters included
best-corrected visual acuity (BCVA) and central macular
thickness (CMT).
The following data from the original articles were being
extracted: first author and year of publication; study site;
study design; sample size and age of the participants; treat-
ment method and follow-up duration; numbers lost to fol-
low-up; and treatment outcome in terms of BCVA and CMT.
FIG. 1. Flowchart of literature search and study selection.
Table 1. Main Characteristics of Studies Included in This Meta-Analysis
Authors
Publication
time (year) Study design Region
Number
of cases
Mean age of
IVB cases
(years)
Mean time
of IVB during
follow-up
Dosage
of IVB
(mg)
Dosage
of IVTA
(mg)
Follow-up
duration
Ding et al.12 2011 Controlled,
randomized
China 32 (IVB 16) 54.6 – 14.2 2.38 1.25 4.0 9 months
Guthoff et al.37 2010 Controlled,
nonrandomized
Germany 18 (IVB 9) 65 – 4 1.3 1.5 8.0 12 months
Lim and Na11 2011 Controlled,
nonrandomized
India 38 (IVB 24) 68.7 – 14.7 3.6 1.25 4.0 12 months
Tao et al.9 2010 Controlled,
nonrandomized
China 72 (IVB 30) 55.15– 15.9 2.7 1.25 4.0 12 months
Wu et al.14 2009 Controlled,
nonrandomized
Taiwan 35 (IVB 13) 59.07– 17.49 1.62 1.25 4.0 12 months
IVB, intravitreal bevacizumab; IVTA, intravitreal triamcinolone acetonide.
Table 2. Comparison of Best-Corrected Visual Acuity at 24 Weeks After Initial Treatment
Between Intravitreal Injection of Bevacizumab Groups and Intravitreal Injection
of Triamcinolone Acenotide Groups
Subgroup
IVB group Triamcinolone group
Authors Mean SD Total Mean SD Total Weight
Mean difference
IV, random, 95% CI
Ding et al.12 0.889 0.568 16 0.802 0.45 16 8.4% 0.09 [ - 0.27, 0.44]
Guthoff et al.37 0.19 0.2 9 0.11 0.19 9 32.7% 0.08 [ - 0.10, 0.26]
Lim and Na11 0.9 0.36 24 0.93 0.41 14 15.9% - 0.03 [ - 0.29, 0.23]
Tao et al.9 0.12 0.27 30 0.13 0.41 42 43.0% - 0.01 [ - 0.17, 0.15]
Total (95% CI) 79 81 100.0% 0.02 [ - 0.08, 0.13]
Heterogeneity: Tau2 = 0.00; w2 = 0.84, df = 3 (P= 0.84); I2 = 0%.
Test for overall effect: Z = 0.46 (P= 0.64).
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Data extraction was conducted by the 2 reviewers indepen-
dently, and discordance was resolved through discussion
until 100% agreement was reached.
A meta-analysis on the effect of IVB or IVTA on macular
edema secondary to CRVO was performed using Cochrane
Review Manager (RevMan; version 5.0 software). The treat-
ment effect was estimated by means of weighted mean de-
viation (WMD) in BCVA and CMT. The incidence of adverse
events such as ocular hypertension was evaluated by the risk
ratio (RR). Random effect models were used for the meta-
analysis, and were verified using the Q test (P < 0.10 was
considered to indicate statistically significant heterogeneity)
and the I2 statistic (values of 25%, 50%, and 75% are con-
sidered to represent low, medium, and high heterogeneity,
respectively). Publication bias was assessed by visually in-
specting a funnel plot.
Results
A total of 69 articles were identified, of which 55 arti-
cles were excluded due to the above-mentioned reasons.
A full review was performed for the remaining 14 arti-
cles. Nine out of 14 were further excluded due to simi-
larities with previous studies from the same group of
authors (Fig. 1). Five articles published between 2005
and 2012 were finally included into the meta-analysis
(Table 1).9,11–14
There were one RCT and 4 nonrandomized controlled
studies (Table 1). The sample sizes varied from 18 to 75
subjects, and mean follow-up durations varied from 9 to 12
months. The treatment outcome estimates were provided for
a total of 92 eyes in the IVB group and 103 eyes in the IVTA
group. In all studies, distribution of age, gender, and history
of CRVO did not vary significantly between the IVB group
and the IVTA group.
Four studies reported data on BCVA at 4 weeks after the
initial treatment. The BCVAs were converted to logarithm
of the minimum angle of resolution (logMAR) vision
and were summarized by means of meta-analysis (I2 = 0%).
The BCVA at 4 weeks after IVB treatment did not vary
significantly when compared to those using IVTA
(WMD = 0.06; 95% CI: - 0.04–0.16; P = 0.27). All the 5
studies reported data on BCVA at 12 weeks after the initial
treatment, and demonstrated low heterogeneity (I2 = 0%).
The improvement in BCVA did not vary significantly
between the IVB and IVTA groups (WMD = 0.03; 95%
CI: - 0.06–0.13; P = 0.51). Four studies reported data on
BCVA at 24 weeks after the initial treatment, and showed
low heterogeneity (I2= 0%). Again, the improvement in
BCVA did not vary significantly between the IVB and IVTA
groups (WMD= 0.02; 95% CI: - 0.08–0.13; P= 0.64) (Table 2)
(Fig. 2).
Four studies reported data on CMT at 4 weeks after the
initial treatment. Low heterogeneity between studies was
detected (I2 = 0%). Changes in CMT at 4 weeks after IVB did
not vary significantly as compared to those using IVTA
(WMD = - 4.97; 95% CI: - 71.41–61.47; P = 0.88). All 5
studies reported data on CMT at 12 weeks after the initial
treatment, and demonstrated low heterogeneity (I2 = 32%).
Changes in CMT also did not vary significantly between the
IVB and IVTA groups (WMD = 20.29; 95% CI: - 50.53–91.12;
P = 0.57). Four studies reported data on CMT at 24 weeks
after the initial treatment, but showed high heterogeneity
(I2 = 58%). Changes in CMT at 24 weeks after IVB treatment
did not vary significantly as compared to those that re-
ceived IVTA (WMD = 67.75; 95% CI: - 35.30–170.79; P =
0.20) (Table 3) (Fig. 3).
All 5 studies reported complications during the follow-
up period, such as intraocular pressure (IOP) rise. No
FIG. 2. Comparison of best-corrected visual acuity at 24
weeks after initial treatment between intravitreal injection of
bevacizumab (IVB) groups and intravitreal injection of tri-
amcinolone acenotide (IVTA) groups in published studies
(from top to bottom): Ding et al.,12 Guthoff et al.,37 Lim
et al.,11 and Tao and Jonas.5
Table 3. Comparison of Central Macular Thickness at 24 Weeks After Initial Treatment
Between Intravitreal Injection of Bevacizumab Groups and Intravitreal Injection
of Triamcinolone Acenotide Groups
Subgroup
IVB group Triamcinolone group Mean difference
Authors Mean SD Total Mean SD Total Weight IV, Random, 95% CI
Ding et al.12 326.38 163.07 16 333.46 121.41 16 31.6% - 7.08 [- 106.70, 92.54]
Guthoff et al.37 514.0 249.0 9 488.0 251.0 9 13.8% 26.00 [- 204.99, 256.99]
Lim and Na11 302.4 198.3 24 263.5 158.8 14 28.7% 38.90 [- 76.05, 153.85]
Tao et al.9 596.5 319.76 30 383.54 212.51 42 25.9% 212.96 [81.72, 344.20]
Total (95% CI) 79 81 100.0% 67.75 [- 35.30, 170.79]
Heterogeneity: Tau2 = 6177.35; w2 = 7.17, df = 3 (P= 0.07); I2 = 58%.
Test for overall effect: Z = 1.29 (P = 0.20).
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patients had IOP rise after IVB, but IOP rise after IVTA was
reported to be as high as 50.5% in one study (52/103). All
cases with IOP rise after injection were controllable by
medication. Low heterogeneity between studies was de-
tected (I2 = 0%). Random-effects model analysis demon-
strated a significant difference between IVB and IVTA in
this regard (RR, relative risk = 0.06; 95% CI: 0.02–0.22;
P < 0.001) (Table 4) (Fig. 4).
Based on funnel plots, no obvious evidence of publication
bias was found for the treatment outcome estimates (BCVA
and CMT at 12 weeks after initial treatment) (Figs. 5 and 6).
Since the number of enrolled studies was low, additional
tests (the Egger’s Method, and the Begg’s method) were used
to measure publication bias, but none was able to detect any
(BCVA at 12 weeks after initial treatment: the Egger’s
method: P = 0.14, the Begg’s method: P = 0.09; CMT at 12
weeks after initial treatment, the Egger’s method: P = 0.26,
the Begg’s method: P = 0.81).
Discussion
Our meta-analysis failed to detect any statistical signifi-
cant difference between the IVB and the IVTA groups, in
terms of BCVA measured at 4, 12, and 24 weeks after base-
line (at 4 weeks: P = 0.27; at 12 weeks: P = 0.51; at 24 weeks:
P = 0.64). Similarly, the difference in reduction in CMT be-
tween the 2 groups also did not vary significantly at 4, 12,
and 24 weeks (at 4 weeks: P= 0.88; at 12 weeks: P = 0.57; at
24 weeks: P = 0.64). However, the rates of IOP rise were
significantly higher in the IVB groups than the IVTA groups
(P < 0.001).
There have been several studies looking into the effect of
bevacizumab in macular edema secondary to CRVO. The
common results were improvements in BCVA, reduction in
CMT on optical coherence tomography (OCT), or im-
provement in electroretinographic outcomes. At the same
time, common shortcomings were the short-term efficacy of
IVB, and the high recurrence rates of macular edema after
the wearing off of its effect. While the dosage varied from
1.25 to 2.0mg, there is no difference in terms of the out-
comes.16–23 On the other hand, similar improvements in
BCVA and CMT after IVTA for CRVO were also observed
in some other reports.4,5,8,24–30 After IVTA, IOP readings
higher than 21/30/35/40 mmHg, was reported in as high
FIG. 3. Comparison of central macular thickness (CMT) at
24 weeks after initial treatment between IVB groups and
IVTA groups in published studies (from top to bottom):
Ding et al.,12 Guthoff et al.,37 Lim et al.,11 and Tao and
Jonas.5
Table 4. Comparison of Intraocular Pressure After Initial Treatment Between Intravitreal
Injection of Bevacizumab Groups and Intravitreal Injection
of Triamcinolone Acenotide Groups
Subgroup
IVB group Triamcinolone group Risk ratio
Authors Events Total Events Total Weight M-H, random, 95% CI
Ding et al.12 0 16 6 16 19.8% 0.08 [0.00, 1.26]
Guthoff et al.37 0 9 6 9 20.7% 0.08 [0.00, 1.19]
Lim and Na11 0 24 4 14 19.1% 0.07 [0.00, 1.15]
Tao et al.9 0 30 29 42 20.4% 0.02 [0.00, 0.37]
Wu et al.14 0 13 7 22 20.0% 0.11 [0.01, 1.77]
Total (95% CI) 92 103 100.0% 0.06 [0.02, 0.22]
Total events 0 52
Heterogeneity: Tau2 = 0.00; w2 = 0.77, df = 4 (P= 0.94); I2 = 0%.
Test for overall effect: Z = 4.35 (P< 0.0001).
FIG. 4. Comparison of increasing intraocular pressure
during follow-ups between IVB groups and IVTA groups in
published studies (from top to bottom): Ding et al.,12 Guthoff
et al.,37 Lim et al.,11 Tao and Jonas,5 and Wu et al.14
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as 36.2/8.5/4.2/1.5% of patients, respectively.5 The Inter-
national Intravitreal Bevacizumab Safety Survey gathered
adverse events after IVB from doctors around the world
using the internet and found that all ocular and systemic
side effects were below 0.21%, including corneal abrasion
and lens injury.31
These results were in agreement with other comparative
studies between IVB and IVTA for the treatment of branch
retinal vein occlusion (BRVO).32–35 In a study by Kwon et al.,
both IVTA- and IVB-treated groups showed improvement
after injections for BRVO, and there was no significant dif-
ference in the visual outcome and macular thickness at
6 months.32 Considering the potential risks with IVTA in-
jections, some authors recommended prescheduled repeated
IVB injections for BRVO cases.33
The findings in our meta-analysis were partly in dis-
agreement with comparative studies between IVB and IVTA
for diabetic macular edema (DME). A recent published meta-
analysis showed that IVTA was more effective in improving
BCVA than IVB in DME, while reduction in CMT was un-
sustainable.36
The main limitation of this study was that the number of
included studies and the total number of subjects were rel-
atively low. This probably reflected the strict inclusion and
exclusion criteria. The included studies, however, originated
from several regions, and all except one9 led to similar con-
clusions in the outcomes measured.
In conclusion, our meta-analysis showed a similar im-
provement BCVA and CMT in CRVO patients after in-
travitreal injections of either IVB or IVTA, but IVB
appeared to be devoid of unfavorable IOP elevation after
injections.
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